Rating Action: Barclays Gives Johnson & Johnson (NYSE:JNJ) Lower Rating. What Is Next?

November 29, 2016 - By Marie Mckinney

Rating Action: Barclays Gives Johnson & Johnson (NYSE:JNJ) Lower Rating. What Is Next?

Johnson & Johnson (NYSE:JNJ) Downgrade

Barclays gave Johnson & Johnson (NYSE:JNJ) shares a new Equal-Weight rating in a an analyst report revealed to investors and clients on Tuesday, 29 November. This is cut from the last Overweight rating.

Johnson & Johnson (NYSE:JNJ) Ratings Coverage

Out of 13 analysts covering Johnson & Johnson (NYSE:JNJ), 7 rate it a “Buy”, 1 “Sell”, while 5 “Hold”. This means 54% are positive. $145 is the highest target while $90 is the lowest. The $116.69 average target is 3.70% above today’s ($112.53) stock price. Johnson & Johnson has been the topic of 38 analyst reports since August 7, 2015 according to StockzIntelligence Inc. Goldman Sachs maintained the stock with “Neutral” rating in Wednesday, April 20 report. The stock of Johnson & Johnson (NYSE:JNJ) has “Hold” rating given on Thursday, August 4 by Jefferies. The stock of Johnson & Johnson (NYSE:JNJ) has “Outperform” rating given on Wednesday, October 7 by RBC Capital Markets. The rating was maintained by Jefferies on Tuesday, March 15 with “Hold”. UBS initiated the shares of JNJ in a report on Tuesday, September 22 with “Buy” rating. Vetr downgraded Johnson & Johnson (NYSE:JNJ) rating on Monday, August 31. Vetr has “Strong-Buy” rating and $106.73 price target. Standpoint Research initiated Johnson & Johnson (NYSE:JNJ) on Friday, May 20 with “Sell” rating. The firm has “Hold” rating given on Tuesday, September 13 by Jefferies. The rating was upgraded by Argus Research on Wednesday, July 20 to “Buy”. As per Wednesday, April 6, the company rating was initiated by Societe Generale.

About 4.06 million shares traded hands. Johnson & Johnson (NYSE:JNJ) has risen 0.19% since April 26, 2016 and is uptrending. It has underperformed by 5.06% the S&P500.

Analysts await Johnson & Johnson (NYSE:JNJ) to report earnings on January, 24 before the open. They expect $1.56 EPS, up 8.33% or $0.12 from last year’s $1.44 per share. JNJ’s profit will be $4.21 billion for 18.03 P/E if the $1.56 EPS becomes a reality. After $1.68 actual EPS reported by Johnson & Johnson for the previous quarter, Wall Street now forecasts -7.14% negative EPS growth.

Insitutional Activity: The institutional sentiment decreased to 0.82 in 2016 Q2. Its down 0.04, from 0.86 in 2016Q1. The ratio is negative, as 49 funds sold all Johnson & Johnson shares owned while 890 reduced positions. 103 funds bought stakes while 703 increased positions. They now own 1.75 billion shares or 5.01% less from 1.84 billion shares in 2016Q1.

Focused Wealth has invested 0.84% of its portfolio in Johnson & Johnson (NYSE:JNJ). Provident Mngmt has 0.11% invested in the company for 4,274 shares. Moreover, Johnson Invest Counsel Incorporated has 0.89% invested in Johnson & Johnson (NYSE:JNJ) for 223,478 shares. Haverford Tru has 1.24M shares for 3.79% of their US portfolio. Arrowpoint Asset Management Lc has invested 0.02% of its portfolio in Johnson & Johnson (NYSE:JNJ). Ahl Llp accumulated 0.06% or 8,447 shares. Mraz Amerine Assoc holds 1.31% or 30,866 shares in its portfolio. Lombardia Capital Prns Ltd Liability holds 0.03% of its portfolio in Johnson & Johnson (NYSE:JNJ) for 3,308 shares. Birinyi Assocs holds 0.61% of its portfolio in Johnson & Johnson (NYSE:JNJ) for 11,600 shares. Bedrijfstakpensioenfonds Voor De Media Pno last reported 10,100 shares in the company. Peavine Cap Mgmt Ltd Liability Corp accumulated 0.13% or 2,340 shares. St James Lc accumulated 0.11% or 7,299 shares. Heritage Wealth Advisors has 1.13% invested in the company for 13,763 shares. Lakeview Partners Limited Company accumulated 19,767 shares or 1.44% of the stock. Investment Counselors Of Maryland Lc reported 12,167 shares or 0.08% of all its holdings.

Insider Transactions: Since June 7, 2016, the stock had 1 insider buy, and 4 selling transactions for $6.89 million net activity. 41,146 shares were sold by Caruso Dominic J, worth $5.14 million. PRINCE CHARLES also bought $99,846 worth of Johnson & Johnson (NYSE:JNJ) on Friday, October 21. 3,000 Johnson & Johnson (NYSE:JNJ) shares with value of $347,381 were sold by Kapusta Ronald A. On Tuesday, June 7 Pruden Gary J sold $1.13M worth of the stock or 9,735 shares.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The company has a market cap of $303.46 billion. The Company’s divisions include Consumer, Pharmaceutical and Medical Devices. It has a 19.72 P/E ratio. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

According to Zacks Investment Research, “Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women’s health fields, nutritional and over-the-counter pharmaceutical products. The company’s Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women’s health products. Johnson & Johnson is based in New Brunswick, New Jersey.”

JNJ Company Profile

Johnson & Johnson, incorporated on November 10, 1887, is a holding company. The Firm and its subsidiaries are engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s divisions include Consumer, Pharmaceutical and Medical Devices. The Company’s primary focus is on products related to human health and well-being. The Company’s subsidiaries operate over 120 manufacturing facilities. The Company’s research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom. The Firm has over 250 operating companies, which conduct business around the world.

More notable recent Johnson & Johnson (NYSE:JNJ) news were published by: Reuters.com which released: “J&J raises Actelion takeover pressure with higher price: source” on November 29, 2016, also Nytimes.com with their article: “Johnson & Johnson Has Its Eye on Actelion” published on November 25, 2016, Thestreet.com published: “Analysts’ Actions — Goldman Sachs, Johnson & Johnson, Pfizer and More” on November 29, 2016. More interesting news about Johnson & Johnson (NYSE:JNJ) were released by: Realmoney.Thestreet.com and their article: “Have Traders in Johnson & Johnson Recently Turned Bullish?” published on November 29, 2016 as well as Thestreet.com‘s news article titled: “Johnson & Johnson: Durable Dividend Payer With Growth” with publication date: November 25, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>